The Association between Age and Clinical Outcomes in Patients with Subclinical Atrial Fibrillation Treated with Apixaban: Insights from the ARTESiA Trial

2 September 2024 (15:51 - 16:03)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Associate Professor Marco Proietti

University of Milan, Milan (Italy)

4 More presentations in this session

Presentation thumbnail

Long-acting Factor XI Inhibition and Periprocedural Bleeding: A Secondary Analysis from AZALEA-TIMI 71

Doctor S. Patel (Boston, US)

Presentation thumbnail

Aspirin and hemocompatibility related adverse events after LVAD implantation in patients with diabetes mellitus, obesity and atrial fibrillation: the ARIES-HM3 randomized clinical trial

Doctor N. Uriel (New York, US)

Presentation thumbnail

Efficacy and safety of anticoagulation in patients with device-detected atrial fibrillation by indication for acetylsalicylic acid therapy

Professor R. Schnabel (Hamburg, DE)

Presentation thumbnail

Changes in Cognitive Function in Patients with Subclinical Atrial Fibrillation Treated with Apixaban or Aspirin: A Sub-Study from the ARTESiA Trial

Doctor L. Rivard (Montreal, CA)

Access the full session

Session thumbnail

Smaller trials, trial updates, and other studies on antiplatelet and antithrombotic therapies

The Event

Event poster

ESC Congress 2024

2 September 2024 15:51 CET

You may be interested in

Congress Presentation

Risk of stroke or systemic embolism according to baseline frequency and duration of subclinical atrial fibrillation: Insights from the ARTESiA trial

Congress Presentation

Incidence and predictors of major bleeding among patients receiving apixaban or aspirin for subclinical atrial fibrillation: insights from the ARTESiA sub-analysis

Congress Session

Smaller trials, trial updates, and other studies on antiplatelet and antithrombotic therapies

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources